Poolbeg Pharma Enhances Scientific Advisory Board with CAR-T Therapy Expert Dr. Adrian Kilcoyne

Poolbeg Pharma has appointed Dr Adrian Kilcoyne to its Scientific Advisory Board, bringing over 20 years of oncology and immunology drug development experience. Kilcoyne previously held chief medical officer roles at Cellectis, Celularity, and Humanigen, and has held senior positions at AstraZeneca, Celgene, Sanofi, Roche, and Eli Lilly. His appointment is expected to support Poolbeg's TOPICAL trial, which is testing its lead drug candidate POLB 001 designed to prevent cytokine release syndrome (CRS) in cancer immunotherapy patients.